Kevin Zikaras
Corporate Officer/Principal at TCR2 THERAPEUTICS INC.
Profile
Kevin Zikaras is currently the Vice President-Development Operations at TCR2 Therapeutics, Inc. He previously worked as the Director-Clinical Development at Actinium Pharmaceuticals, Inc. and as the Manager-Clinical Protocol at Bristol Myers Squibb Co. Zikaras received his undergraduate degree from Bowdoin College and his graduate degree from Northeastern University.
He also holds an MBA from Johnson Graduate School of Management and a graduate degree from Weill Cornell Medical College.
Kevin Zikaras active positions
| Companies | Position | Start |
|---|---|---|
| TCR2 THERAPEUTICS INC. | Corporate Officer/Principal | 31/05/2018 |
Former positions of Kevin Zikaras
| Companies | Position | End |
|---|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | - |
| ACTINIUM PHARMACEUTICALS, INC. | Corporate Officer/Principal | - |
Training of Kevin Zikaras
| Bowdoin College | Undergraduate Degree |
| Northeastern University | Graduate Degree |
| Weill Cornell Medical College | Graduate Degree |
| Johnson Graduate School of Management | Masters Business Admin |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| ACTINIUM PHARMACEUTICALS, INC. | Health Technology |
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| Private companies | 1 |
|---|---|
TCR2 Therapeutics, Inc.
 TCR2 Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology TCR2 Therapeutics, Inc. is a clinical-stage cell therapy company, which engages in the development of biological drugs and engineering T-cells for cancer therapy. It is also involved in the research and collaboration with academic laboratories and industry partners in the field of T-cell immunology, cell therapy, gene editing, and process development. The company was founded by Patrick A. Baeuerle on May 29, 2015 and is headquartered in Cambridge, MA. | Health Technology |
- Stock Market
- Insiders
- Kevin Zikaras
